FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Lupin Pharmaceuticals Irbesartan and Hydrochlorothiazide Tablets Recall

Irbesartan and Hydrochlorothiazide Tablets USP, 150/12

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class II
Reported by FDA
Nov 10, 2021
Recall ID
D-0089-2022
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Irbesartan and Hydrochlorothiazide Tablets starting Oct 12, 2021. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0089-2022 on Nov 10, 2021. Reason: CGMP Deviations: impurity N-nitrosoirbesartan detected in API. Status: Terminated.

Why it was recalled

CGMP Deviations: impurity N-nitrosoirbesartan detected in API

Product description

Irbesartan and Hydrochlorothiazide Tablets USP, 150/12.5 mg a) 30 count (NDC 68180-413-06) and b) 90 count (NDC 68180-413-09) bottles, Rx only

Lot numbers, UPCs & expiration codes

a) Lot# H804537, exp. date 30/09/2021 H805148, exp. date 31/10/2021 H900063, exp. date 31/10/2021 H900522, exp. date 31/12/2021 H901582, exp. date 31/01/2022 b) Lot# H000963, exp. date 30/04/2022 H804507, exp. date 30/04/2022 H804536, exp. date 30/09/2021 H805070, exp. date 31/10/2021 H805149, exp. date 31/10/2021 H900064, exp. date 31/12/2021 H900523, exp. date 31/01/2022 H901583, exp. date 30/04/2022 H902530, exp. date 30/04/2022

Where it was sold

Product was distributed to major distributors who may have further distributed the product nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0089-2022
Classification
Class II
Status
Terminated
Recall initiated
Oct 12, 2021
FDA report date
Nov 10, 2021
Quantity
63,408 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-0089-2022, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
88856
Address
Harborplace Tower
Address (line 2)
111 S Calvert St Fl 21st
Code information
a) Lot# H804537, exp. date 30/09/2021 H805148, exp. date 31/10/2021 H900063, exp. date 31/10/2021 H900522, exp. date 31/12/2021 H901582, exp. date 31/01/2022 b) Lot# H000963, exp. date 30/04/2022 H804507, exp. date 30/04/2022 H804536, exp. date 30/09/2021 H805070, exp. date 31/10/2021 H805149, exp. date 31/10/2021 H900064, exp. date 31/12/2021 H900523, exp. date 31/01/2022 H901583, exp. date 30/04/2022 H902530, exp. date 30/04/2022
Postal code
21202-6174
Report date
Nov 10, 2021
Product type
Drugs
Recall number
D-0089-2022
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
63,408 bottles
Termination date
Jan 30, 2023
Reason for recall
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
Voluntary / mandated
Voluntary: Firm initiated
Product description
Irbesartan and Hydrochlorothiazide Tablets USP, 150/12.5 mg a) 30 count (NDC 68180-413-06) and b) 90 count (NDC 68180-413-09) bottles, Rx only
Distribution pattern
Product was distributed to major distributors who may have further distributed the product nationwide.
Recall initiation date
Oct 12, 2021
Initial firm notification
Letter
Center classification date
Nov 1, 2021

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0089-2022, published Nov 10, 2021. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls